Investec Reiterates Buy on Dechra Pharmaceuticals (DPH)
Dechra Pharmaceuticals (LON: DPH)‘s stock had its “buy” rating reaffirmed by research analysts at Investec in a report released on Tuesday. They currently have a $10.80 (670 GBX) target price on the stock.
Shares of Dechra Pharmaceuticals opened at 617.00 on Tuesday. Dechra Pharmaceuticals has a 52 week low of GBX 367.287 and a 52 week high of GBX 639.50. The stock’s 50-day moving average is currently GBX 561.3. The company’s market cap is £536.0 million.
Dechra Pharmaceuticals PLC (Dechra) is an international veterinary pharmaceutical company. The Company operates in four segments: Product Development, European Pharmaceuticals, US Pharmaceuticals and Services.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.